PMC7724000_01
(a, b) Cervical mass at presentation, (c, d) Extensive calcifications in the cervix and uterus after two HPP cycles, (e, f) Residual cervical mass after four HPP cycles.
gr2.jpg
PMC7724000_01_gr2.jpg
fig0010
May of 2005. MRI of the abdomen and pelvis in June of 2005 revealed a 3.1 x 1.8 x 2.8 cm mass infiltrating the dorsal vaginal vault, right rectouterine plica up into the rectum, and presacral soft tissues on the left (Fig. 2a, b). CT of the abdomen and pelvis from September of 2005 after two cycles of HPP demonstrated extensive calcifications in the cervix and uterus (Fig. 2c, d). MRI of the abdomen and pelvis from December of 2005 after two additional HPP cycles demonstrated residual necrotic cervical mass (Fig. 2e, f).
PMC7724000_02
(a) Cervical mass at diagnosis in August of 2012 (left) and (b) after the 1st HPP, (c, d) FDG PET-CT two months after 3rd treatment (left) and one year after (right).
gr3.jpg
PMC7724000_02_gr3.jpg
fig0015
CT of the abdomen and pelvis from April of 2013 revealed a 3.86 x 5.83 cm cervical mass (Fig. 3a). MRI of the abdomen and pelvis from May of 2013 after two HPP cycles demonstrated residual cervical mass 1.89 x 2.34 cm (Fig. 3b). There was no evidence of disease on the follow up FDG PET-CT in August of 2014 (Fig. 3c, d).
PMC7724000_03
(a, b) cervical mass before treatment on contrast-enhanced CT and FDG PET-CT, (c, d) cervix 3 months after the last HPP.
gr4.jpg
PMC7724000_03_gr4.jpg
fig0020
CT abdomen and pelvis and FDG PET-CT performed in February of 2020 confirmed a highly metabolic cervical lesion 3.61 x 4.29 cm (Fig. 4a, b).